Fosun Pharma: The holding subsidiary's drug has been approved for clinical trials in late-stage solid tumors

Recently, Shanghai Fosun Pharmaceutical Holdings subsidiary HENLIUS received approval from the National Medical Products Administration to conduct clinical trials for the injection HLX43 in combination with HLX07 for the treatment of advanced/metastatic solid tumors, with plans to carry out Phase Ib/II trials domestically. HLX43 is a PD-L1 targeted antibody-drug conjugate, while HLX07 is an innovative biopharmaceutical targeting the EGFR. As of September 30, 2025, multiple clinical studies for HLX43 are being conducted in various locations worldwide, and several Phase II clinical studies related to HLX07 are underway domestically. As of August, the total R&D investment for this treatment plan has reached approximately 150,000 yuan, and there are currently no similar combination drugs approved for marketing globally. Since the drug is still in the clinical trial stage, there are risks associated with R&D, and investors are reminded to pay attention to investment risks